Company news
Emv Capital Plc (LSE:EMVC) news
Every Emv Capital Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Portfolio Update and Presentation
July 13, 2026
Portfolio Update: Glycotest and ProAxsis
July 1, 2026
AMR Bio: Commercial Update
May 21, 2026
Final Results for the year ended 31 December 2025
May 19, 2026
Notice of Final Results
May 14, 2026
Trading and Portfolio Update
February 2, 2026
PDMR Dealing
January 8, 2026
Sofant Technologies: Fundraising
December 23, 2025
Director/PDMR Dealing
December 19, 2025
Wanda Health: Fundraising and Business Update
December 10, 2025
Share Issue, PDMR Dealings & Total Voting Rights
December 8, 2025
TR-1
December 4, 2025
Expansion of Senior Finance Leadership Team
November 24, 2025
Portfolio Update
November 20, 2025
Interim Results and Investor Presentation
September 30, 2025
Asset Purchase Agreement with Destiny Pharma
September 22, 2025
Notice of Interim Results
September 18, 2025
Result of AGM
June 30, 2025
Office move and Related Party Transaction
June 30, 2025
Q-Bot Limited Fundraising
June 27, 2025
Notice of AGM and Annual Report & Accounts
June 6, 2025
Director/PDMR Shareholding
June 4, 2025
Preliminary results for the year ended 31 Dec 2024
June 4, 2025
PDS: Q1 Results and Clinical and Corporate Update
May 14, 2025
PDS: Q4 Results and Clinical Programs Update
March 27, 2025
PDS: VERSATILE-003 Phase 3 Clinical Trial
March 7, 2025
PDS: up to $22mn Registered Direct Offering
February 27, 2025
PDS Biotech reaffirms guidance for clinical trial
February 5, 2025
ProAxsis: Status Update and Proposed Fundraise
February 3, 2025
Grant of Share Options
December 31, 2024
Q-Bot Fundraising
December 31, 2024
Wanda Health Fundraising
December 9, 2024
Close of Fundraising and Result of Retail Offer
December 5, 2024
Result of Subscription
December 3, 2024
WRAP Retail Offer
December 3, 2024
Proposed Subscription and Retail Offer; Update
December 3, 2024
Replacement RNS: PDS: Update, 3rd Quarter Results
November 14, 2024
PDS: Clinical Programs Update, 3rd Quarter Results
November 14, 2024
PDS: 36-Month Overall Survival Rate announcement
October 2, 2024
Interim Results
September 30, 2024
Name change and AIM Rule 26 website
September 26, 2024
PDS: Updated Results, VERSATILE-002 Phase 2 Trial
September 16, 2024
PDS Biotech: Business Update and Q2 2024 Results
August 13, 2024
Replacement RNS: PDS Biotech Aligns with FDA
August 2, 2024
PDS Biotech Aligns with FDA on Phase 3 Trial
August 2, 2024
Notice of AGM
June 18, 2024
Preliminary Results for the year ended 31 Dec 2023
June 13, 2024
Notice of Results and Investor Presentation
May 31, 2024
DeepTech Recycling: Fundraising, Business Update
May 31, 2024
Investment in Wanda, related party transactions
May 28, 2024